Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diltiazem and granulomatous hepatitis.

N S Sarachek, R L London, T J Matulewicz

    Gastroenterology
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Diltiazem use can cause granulomatous hepatitis, a liver condition confirmed by biopsy. Healthcare providers should monitor patients for liver injury signs while on diltiazem.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Gastroesophageal tumor embolization to the popliteal arteries.

    Journal of vascular surgery·1997
    Same author

    Venous valvular assessment after retrograde catheterization.

    Journal of vascular and interventional radiology : JVIR·1996
    Same author

    Unusual symmetric common carotid lesions and oral iodine 131 for hyperthyroidism.

    Journal of vascular surgery·1989
    Same author

    Increased colonic motility during exposure to a stressful situation.

    Digestive diseases and sciences·1985
    Same author

    Diverticulum of the urinary bladder.

    American family physician·1984
    Same author

    An immediate hemolytic transfusion reaction due to anti-C and a delayed hemolytic transfusion reaction due to anti-Ce+e: hemoglobinemia, hemoglobinuria and transient impaired renal function.

    Vox sanguinis·1984

    Area of Science:

    • Hepatology
    • Clinical Pharmacology

    Background:

    • Diltiazem is a widely prescribed calcium channel blocker for cardiovascular conditions.
    • Drug-induced liver injury (DILI) encompasses a range of hepatic pathologies.
    • Granulomatous hepatitis is a specific pattern of liver inflammation.

    Observation:

    • A case of granulomatous hepatitis was diagnosed in a patient undergoing diltiazem therapy.
    • Liver biopsy confirmed the presence of granulomas, indicative of granulomatous hepatitis.
    • The clinical presentation included fever and laboratory abnormalities suggestive of hepatic injury.

    Findings:

    • A biopsy-proven case of granulomatous hepatitis was directly linked to diltiazem administration.
    • The histological findings were consistent with a drug-induced hepatic reaction.

    Related Experiment Videos

  • Cessation of diltiazem was implied as a management strategy, though not explicitly stated.

    • Implications:

    • Clinicians must maintain a high index of suspicion for diltiazem-induced granulomatous hepatitis.
    • Early recognition and diagnosis are crucial for preventing severe hepatic damage.
    • Awareness of this rare complication can guide patient management and improve outcomes.